Recent Updates
Recently added Catalysts

MT-601 dose 200 million cells

Phase 1

Pancreas Cancer | Small molecule | Oncology |Marker Therapeutics, Inc.|Last Updated: May 13, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDDMC
Total Trials1
Total Enrollment38

FDA Designations

No designations recorded

Clinical trial landscape

MT-601 dose 200 million cells · 1 trial · 3 indications

Phase 1 1
NCT06549751MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic CancerPancreas Cancer
NOT YET_RECRUITING38 Analytics
PHASE1NOT YET_RECRUITING
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Pancreas Cancer
NCT0654975138
Unlock trial analytics

Study Endpoints

Primary Endpoints

During Dose Escalation - determine the MTD, recommended expansion dose, or MPD of MT-601 administered during maintenance capacitabine following treatment with FOLFIRINOX (FFX) or NALIRIFOX (NLX).
Through study completion. Approximately 24 months

Dose-limiting toxicities (DLTs)

Secondary Endpoints

During Dose Expansion - evaluate the safety profile of MT-601
Through study completion. Approximately 2.5 years
During Dose Escalation and Dose Expansion - determine the Efficacy of MT-601
Through study completion. Approximately 2.5 years
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Cohort 1 / MT-601 dose 400 million cellsEXPERIMENTALMT-601 dose 400 million cells
Cohort 3 / MT-601 1200 million cellsEXPERIMENTALMT-601 dose 1200 million cells
Cohort 2 / MT-601 800 million cellsEXPERIMENTALMT-601 dose 800 million cells
Cohort -1 / MT-601 dose 200 million cellsEXPERIMENTALExperimental: Cohort -1 / MT-601 dose 200 million cells
Dose ExpansionEXPERIMENTALThe Dose Expansion portion will begin after completion of the Dose Escalation portion with recommended dose of MT-601.

Interventions

NameTypeDescription
MT-601 dose 200 million cellsDRUGMT-601 Dose 200 million cells
MT-601 dose 400 million cellsDRUGMT-601 Dose 400 million cells
MT-601 dose 800 million cellsDRUGMT-601 Dose 800 million cells
MT-601 dose 1200 million cellsDRUGMT-601 Dose 1200 million cells
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Informed Consent 2. Age ≥ 18 years 3. ECOG performance status of 0 to 1 4. Cytologically or histologically confirmed, locally advanced, unresectable or metastatic pancreatic adenocarcinoma (pancreatic carcinomas with at least some component of adenocarcinoma included). 5. Mea...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about MT-601 dose 200 million cells

What is MT-601 dose 200 million cells used for?

MT-601 dose 200 million cells is an investigational therapy being studied for the treatment of pancreas cancer, specifically in patients with locally advanced unresectable or metastatic pancreatic cancer. It is currently in Phase 1 clinical development and has not been approved by the FDA.

Who makes MT-601 dose 200 million cells?

MT-601 dose 200 million cells is being developed by Marker Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol MRKR. The company is conducting a Phase 1 clinical trial to evaluate this investigational therapy in patients with pancreatic cancer.

What phase is MT-601 dose 200 million cells in?

MT-601 dose 200 million cells is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA. The ongoing Phase 1 trial is designed to evaluate the therapy in patients with locally advanced unresectable or metastatic pancreatic cancer.

What clinical trials is MT-601 dose 200 million cells in?

MT-601 dose 200 million cells is being studied in a Phase 1 clinical trial with the identifier NCT06549751. The trial, titled 'MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer', is not yet recruiting and has an estimated enrollment of 38 participants in the United States.

Is MT-601 dose 200 million cells the same as MT-601?

MT-601 dose 200 million cells refers to a specific dose of the investigational therapy MT-601. The clinical trial NCT06549751 evaluates MT-601 at the 200 million cell dose level in patients with pancreatic cancer. The therapy is being developed by Marker Therapeutics, Inc.